NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the launch of atropine.co…
Author: Business Wire
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the thir…
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and fi…
Warby Parker Announces Third Quarter 2022 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2022. “Thanks to our team’s hard work…
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that it has initiated startup…
National Vision Holdings, Inc. Reports Third Quarter 2022 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the third quarter ended October 1, 2022. “The National Vision team continues to progress our key gr…
NovaBay Pharmaceuticals to Hold Third Quarter 2022 Conference Call on November 14
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2022 after market close on Monday, November 14, 2022 and will hol…
Biometric Sensors Global Market Report 2022: Capacitive, Optical, Thermal, Ultrasound, Electric Field, Voice, Finger, Hand, Facial, Iris, Vein – Long-term Forecasts to 2026 & 2031 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Biometric Sensor Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global biometric sensor market is expected to grow from $2.30 billion in 2021 to $2.69 billion in 2022 at a compou…
Hudson Inks Expanded Agreement With Sunglass Hut To Operate New Standalone Travel Retail Stores in North America
EAST RUTHERFORD, N.J.–(BUSINESS WIRE)–Hudson, a Dufry company and travel experience leader with more than 1,000 stores in airports, commuter hubs, landmarks and tourist destinations across North America, today announced an expansion of its partnershi…
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for …
Capri Holdings Limited Announces Second Quarter Fiscal 2023 Results
LONDON–(BUSINESS WIRE)–Capri Holdings Limited (NYSE:CPRI), a global fashion luxury group, today announced its financial results for the second quarter of Fiscal 2023 ended October 1, 2022. Second Quarter Fiscal 2023 Highlights Revenue increased 8.6% …
Global Color Blind Glasses Market Research Report to 2027 – Featuring Carelust, Colorlite, CooperVision and EnChroma Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Color Blind Glasses Market Research Report by Type, Application, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Color Blind Glasses …
The Worldwide Ocular Adhesives & Sealants Industry is Expected to Reach $376.7 Million by 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Adhesives & Sealants Market Research Report by Product, Application, End User, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Gl…
MediPrint™ Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset
SAN DIEGO–(BUSINESS WIRE)–MediPrint™ Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset
Aviceda Announces Additional World-Class Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmology
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a clinical-stage biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and chronic, non-resol…
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
BEDFORD, Mass–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today re…
Oxular Limited nomina James Jogerst, veterano del settore, a Chief Business Officer
OXFORD, Inghilterra–(BUSINESS WIRE)–Oxular Limited, un’azienda terapeutica retinica in fase clinica che sviluppa trattamenti mirati di lunga durata per i disturbi della retina al fine di migliorare la visione dei pazienti, ha annunciato oggi la nomin…
Oxular Limited ernennt Branchenveteran James Jogerst zum Chief Business Officer
OXFORD, Großbritannien–(BUSINESS WIRE)–Oxular Limited, ein Unternehmen mit Spezialisierung auf Netzhaut-Therapeutika im klinischen Stadium, das nachhaltige und zielgerichtete Behandlungen für Netzhauterkrankungen entwickelt, um die Sehkraft der Patie…
Oxular Limited benoemt industrieveteraan James Jogerst tot Chief Business Officer
OXFORD, Engeland–(BUSINESS WIRE)–Oxular Limited, een bedrijf op het gebied van netvliestherapie in klinische fase dat langdurige gerichte behandelingen voor netvliesaandoeningen ontwikkelt om het gezichtsvermogen van patiënten te verbeteren, heeft va…